3D intradermal bioprinting of reconstructive anti-aging biological solutions

• Grant number: 20/09687-2
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Duration: April 01, 2021 - March 31, 2022
• Field of knowledge: Interdisciplinary Subjects
• Principal Investigator: Janaina de Andrea Dernowsek
• Grantee: Janaina de Andrea Dernowsek
• Host Company: Bio.Inn Ltda
• CNAE: Fabricação de preparações farmacêuticas ; Pesquisa e desenvolvimento experimental em ciências físicas e naturais ; Atividades profissionais, científicas e técnicas não especificadas anteriormente
• City: São Paulo
• Associated scholarship(s): 21/07340-8 - Bioinks formulations for 3D tissue bioprinting, BP.TT; 21/04033-7 - Crosslinking of collagen solution with photochemical method for intradermal bioprinting, BP.TT

Abstract

Recent advances in additive manufacturing have enabled 3D printing of biocompatible materials, cells, and support components in complex biological tissues. Nowadays, the 3D bioprinting process can be adapted to produce fabrics in a variety of shapes and structural complexities, in addition to obtaining specific chemical, biomechanical and biological properties, aiming at the creation of biomodels that mimic fabrics close to the real ones. This project aims to develop a process for obtaining ultrapure human bioidentical collagen from bioprinted tissues with the potential for future scale production. A second objective is to develop an innovative intradermal crosslinking method for type 1 collagen for the development of a new generation of anti-aging dermal fillers using 3D fabric biofabrication. The process we want to develop has unique factors because it is extracted from bioprinted tissues using the bioprinting technology of human cells outlined by the author of the project and produced innovatively, accompanied by an extraction process that maintains the nobility of the protein, maintaining the structure original collagen fibrils (a process without similar found in the search for anteriority) and conducive to crosslinking processes that allow for greater longevity in the dermis in injectable applications (figure 1). The result is a high-purity solution with unique characteristics for applications in the cosmetic, pharmaceutical, dental and medical industries, and in a specific targeting the future co-development with the pharmaceutical industry of a new generation of anti-aging dermal filler, the market designed in 10 billion of dollars in 2026 and growth of 8% per year. In an interview with more than 100 people in the industry and 10 aesthetic medicine specialists, the hypothesis that there is potential for obtaining a product with significant competitive advantages compared to the current dermal filler alternatives was validated. The solution differs from alternatives based on hyaluronic acid in that fibrous collagen provides greater durability for applications because of its greater capacity for cross-linking and promoting the biostimulation of the skin's collagen. It differs from alternatives of synthetic compounds/collagen of animal origin in that it brings less risk of an adverse reaction, given that we are proposing the use of bioidentical organic compounds to humans. As a project methodology, we will carry out the proof of concept of the process in six main steps: 2D cell culture and production of spheroids, hydrogel formulation, bioink preparation, bioprinting, collagen extraction, quality/safety analysis and crosslinking. The expected result of the research is the validation of the proposed biological input production process with the expected purity, fibrillar and crosslinking properties expected for type I collagen bioidentical to human, making it attractive to the aesthetic industry. This work opens opportunities for the development of a new generation of dermal fillers using the most innovative in the field of tissue biofabrication and would advance in the field of non-invasive medicine. (AU)